Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

EARLY_PHASE1

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-29

Study Completion Date

2023-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This early phase I trial studies how well levorphanol works as a second line opioid in reducing pain in patients with cancer that may have spread to other places in the body. Levorphanol may work better in controlling cancer pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830

Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia +8 more

TERMINATED NA

Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain

NCT00634010

Advanced Cancer Solid Tumors

TERMINATED PHASE3

Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain

NCT00378937

Pain Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE4

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

NCT06232577

Intra-abdominal Cancer

ACTIVE_NOT_RECRUITING PHASE2

Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain

NCT02084355

Cancer Pain

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To determine the proportion of successful opioid rotation (OR) from morphine equivalent daily dose (MEDD) to levorphanol at the primary end point.

SECONDARY OBJECTIVES:

I. To determine the median opioid rotation ratio (ORR) in patients undergoing successful opioid rotations from morphine equivalent daily dose (MEDD) to levorphanol in the Supportive Care Center (SCC) or Pain Clinic.

II. To determine the effect of levorphanol on cancer pain (as measured by change in Edmonton Symptom Assessment System's \[ESAS\] pain item from baseline) in cancer outpatients undergoing opioid rotation to levorphanol at the primary end point of treatment.

III. To determine the association between the opioid rotation ratio from MEDD to levorphanol and baseline MEDD prior to opioid rotation.

IV. Measure levorphanol related side effects using the opioid side effect scale at day 10 +/- 1 of starting levorphanol.

V. Determine what percentage of patients rotated to levorphanol achieve their personalized pain goal.

VI. Determine the predictors of successful opioid rotation from other opioids to levorphanol.

OUTLINE:

Patients receive levorphanol orally (PO) every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine, hydromorphone, oxycodone, and oxymorphone for breakthrough pain. Patients may continue levorphanol for an additional 6-8 months if it is determined by the Principal Investigator the patient can continue.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supportive care (levorphanol, opioid regimen)

Patients receive levorphanol PO every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine, hydromorphone, oxycodone, and oxymorphone for breakthrough pain. Patients may continue levorphanol for an additional 6-8 months if it is determined by the Principal Investigator the patient can continue.

Group Type EXPERIMENTAL

Hydrocodone

Intervention Type DRUG

Given by PO

Hydromorphone

Intervention Type DRUG

Given by PO

Levorphanol

Intervention Type DRUG

Given PO

Morphine

Intervention Type DRUG

Given by PO

Oxycodone

Intervention Type DRUG

Given by PO

Oxymorphone

Intervention Type DRUG

Given by PO

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrocodone

Given by PO

Intervention Type DRUG

Hydromorphone

Given by PO

Intervention Type DRUG

Levorphanol

Given PO

Intervention Type DRUG

Morphine

Given by PO

Intervention Type DRUG

Oxycodone

Given by PO

Intervention Type DRUG

Oxymorphone

Given by PO

Intervention Type DRUG

Questionnaire Administration

Ancillary studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

(-)-Hydromorphone Dihydromorphinone Hydromorphon Oxycodone SR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients seen in the SCC or Pain Clinic with a diagnosis of cancer with or without evidence of metastatic disease
* Diagnosis of cancer related pain currently treated with first line strong oral opioid analgesics such as morphine, oxycodone, oxymorphone, hydromorphone or hydrocodone
* Age 18 or older
* Able to complete study assessments
* Individual is willing to sign written informed consent
* Patients who are classified as being opioid tolerant by receiving a baseline MEDD of \>= 60 mg
* Patients who are local and able to follow-up in the SCC or Pain Clinic within 30 days if necessary
* Eastern Cooperative Oncology Group (ECOG) performance status of =\< 3

Exclusion Criteria

* Cognitive impairment with a Memorial Delirium Assessment Scale (MDAS) score of 7 or higher or diagnosed with neurocognitive impairment by the treating SCC or Pain Clinic physician
* Renal insufficiency defined as estimated glomerular filtration rate of \< 60
* Hepatic insufficiency defined as transaminitis (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] \> 3 times the highest normal value) or hyperbilirubinemia of \> 1.5 times the highest normal value
* Non-English speaking participants as not all assessments are validated in other languages
* Presence of neuropathic pain as a primary pain syndrome
* Non-malignant pain
* Patients with history of alcohol or substance abuse by using Cut-down, Annoyed, Guilty, Eye-opener adapted to include Drug use questionnaire (CAGE-AID) score of 2 or higher; Pain Clinic: Screener and Opioid Assessment for Patients with Pain (SOAPP) score of 7 or higher. In the unlikely event that CAGE-AID or SOAPP is not present in patient's chart, a CAGE-AID questionnaire will be administered after obtaining verbal consent for screening
* Patients receiving methadone due to reasons such as long and variable half-life
* Patients receiving scheduled benzodiazepines due to the risk of excessive sedation
* Patients with a MEDD of \> 300
* Unable or unwilling to sign consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No